The main campus, Technion City, is a 300-acre site located on Mount Carmel in Haifa that comprises 100 buildings and is frequented by thousands of people every day. There are 18 academic departments in engineering, natural sciences, medicine and architecture, as well as about 42 research centers, 11 research institutes and 10 centers of excellence. These serve the Technion staff, which includes over 620 faculty members, 460 Clinicians, Adjuncts and Instructors, 1,000 Technical and Administrative staff and 58 spin-off companies. At present there are approximately 9,300 undergraduate students, 2,800 M.Sc. students and 1000 Ph.D., M.D. and D.Sc. students – a total of about 13,100 students. To date, Technion has awarded around 100,000 degrees.
The Faculty of Biotechnology and Food Engineering in the Technion is one of few in the world that combines the areas of biotechnology and food under one roof, offering a combined degree (biotechnology and food engineering) with specialization in one of the two areas, so that Faculty graduates can integrate both in the biotechnology industry (which is relatively young) and the food industry.
Our vision at The Lab for Cancer Drug Delivery & Cell Based Technologies is to harness biological and engineering knowledge and expertise to design novel medical solutions by means of drug-delivery, cell-based and cell-free therapies, and biomedical and tissue engineering. Our group intends to use a unique targeted delivery system, named Nano-Ghosts (NG) and derived from the cytoplasmatic membranes of mesenchymal stem cells, to selectively deliver various bioactives to support cartilage regeneration. The group consists of 11 post-docs, Ph.D, and M.Sc students and 4 research associates, and is headed by Prof. Marcelle Machluf whose works were cited almost 2,500 times. The lab head will supervise the ESRs appointed at the Technion and Dr. Tomer Bronshtein will be the project manager.
The first ESR appointed at the Technion, within the TargetCaRe framework, will investigate the possibility of using NGs to support cartilage regeneration. To achieve this, various therapeutics will be loaded into the NGs, and their ability to selectively target and ameliorate cartilage inflammation will be studied.